These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28301521)

  • 1. Lysosomal adaptation: How cells respond to lysosomotropic compounds.
    Lu S; Sung T; Lin N; Abraham RT; Jessen BA
    PLoS One; 2017; 12(3):e0173771. PubMed ID: 28301521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high content screening assay for identifying lysosomotropic compounds.
    Nadanaciva S; Lu S; Gebhard DF; Jessen BA; Pennie WD; Will Y
    Toxicol In Vitro; 2011 Apr; 25(3):715-23. PubMed ID: 21184822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function.
    Pisonero-Vaquero S; Medina DL
    Curr Drug Metab; 2017; 18(12):1147-1158. PubMed ID: 28952432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of membrane trafficking perturbation to retinal toxicity.
    Khoh-Reiter S; Sokolowski SA; Jessen B; Evans M; Dalvie D; Lu S
    Toxicol Sci; 2015 Jun; 145(2):383-95. PubMed ID: 25771199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lysosomotropic molecules on cellular homeostasis.
    Kuzu OF; Toprak M; Noory MA; Robertson GP
    Pharmacol Res; 2017 Mar; 117():177-184. PubMed ID: 28025106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction.
    Funk RS; Krise JP
    Mol Pharm; 2012 May; 9(5):1384-95. PubMed ID: 22449202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death.
    Villamil Giraldo AM; Appelqvist H; Ederth T; Öllinger K
    Biochem Soc Trans; 2014 Oct; 42(5):1460-4. PubMed ID: 25233432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin.
    Holz FG; Schütt F; Kopitz J; Eldred GE; Kruse FE; Völcker HE; Cantz M
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):737-43. PubMed ID: 10067978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress.
    Raben N; Puertollano R
    Annu Rev Cell Dev Biol; 2016 Oct; 32():255-278. PubMed ID: 27298091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of lysosomotropic compounds based on the distribution and size of lysosomes.
    Seo I; Jha BK; Lim JG; Suh SI; Suh MH; Baek WK
    Biochem Biophys Res Commun; 2014 Jul; 450(1):189-94. PubMed ID: 24878535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.
    Zhitomirsky B; Assaraf YG
    Oncotarget; 2017 Jul; 8(28):45117-45132. PubMed ID: 28187461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells.
    Yoon YH; Cho KS; Hwang JJ; Lee SJ; Choi JA; Koh JY
    Invest Ophthalmol Vis Sci; 2010 Nov; 51(11):6030-7. PubMed ID: 20574031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes.
    Schütt F; Bergmann M; Holz FG; Kopitz J
    Graefes Arch Clin Exp Ophthalmol; 2002 Dec; 240(12):983-8. PubMed ID: 12483320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane.
    Stark M; Silva TFD; Levin G; Machuqueiro M; Assaraf YG
    Cells; 2020 Apr; 9(5):. PubMed ID: 32349204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition.
    Collins KP; Witta S; Coy JW; Pang Y; Gustafson DL
    J Pharmacol Exp Ther; 2021 Feb; 376(2):294-305. PubMed ID: 33172973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the roles of autophagy and lysosomal trafficking defects in intracellular distribution-based drug-drug interactions involving lysosomes.
    Logan R; Kong A; Krise JP
    J Pharm Sci; 2013 Nov; 102(11):4173-80. PubMed ID: 23970383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomotropic compounds and spermine enzymatic oxidation products in cancer therapy (review).
    Agostinelli E; Seiler N
    Int J Oncol; 2007 Sep; 31(3):473-84. PubMed ID: 17671672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sub-lethal oxidative stress induces lysosome biogenesis via a lysosomal membrane permeabilization-cathepsin-caspase 3-transcription factor EB-dependent pathway.
    Leow SM; Chua SX; Venkatachalam G; Shen L; Luo L; Clement MV
    Oncotarget; 2017 Mar; 8(10):16170-16189. PubMed ID: 28002813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells.
    Zang Y; Beard RL; Chandraratna RA; Kang JX
    Cell Death Differ; 2001 May; 8(5):477-85. PubMed ID: 11423908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of lysosomotropism to autophagy perturbation.
    Ashoor R; Yafawi R; Jessen B; Lu S
    PLoS One; 2013; 8(11):e82481. PubMed ID: 24278483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.